Nanotechnology Based Approach for Hepatocellular Carcinoma Targeting

Area of Science:

• Oncology
• Nanotechnology
• Drug Delivery

Background:

• Hepatocellular carcinoma (HCC) presents significant global health challenges due to high incidence and mortality rates.
• Conventional chemotherapy for HCC often shows limited efficacy because of poor site-specific drug targeting.
• There is a critical need for innovative therapeutic strategies to improve HCC treatment outcomes.

Purpose of the Study:

• To review the application of nanocarrier systems for hepatocellular carcinoma (HCC) treatment.
• To highlight ligand-based, receptor-specific targeting strategies in nanomedicine for HCC management.
• To provide insights into current HCC drug therapies and regulatory aspects of nanomedicine approval.

Main Methods:

• Review of current literature on nanocarrier systems in HCC treatment.
• Analysis of various nanocarrier types, including liposomes, nanoparticles, and micelles.
• Examination of ligand-based, receptor-specific targeting strategies for HCC nanomedicine.

Main Results:

• Nanomedicines, utilizing lipidic and polymeric composites, show promise for HCC treatment.
• Various nanocarriers (liposomes, nanoparticles, nanotubes, micelles, quantum dots) demonstrate high site-specificity and therapeutic efficiency.
• Ligand-based targeting strategies enhance the clinical effectiveness of nanocarriers in HCC therapy.

Conclusions:

• Nanotechnology-based drug delivery systems represent a significant advancement in HCC treatment.
• Targeted nanocarriers offer improved efficacy and specificity compared to conventional chemotherapy for liver cancer.
• Further research and regulatory considerations are essential for the clinical translation of nanomedicines for HCC.